Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
Follow CHRS
Coherus Oncology, Inc. (CHRS) Piotroski F-score
Coherus Oncology, Inc.'s Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, up from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | 2.00 |
| FY2024 | 4 | 1.00 |
| FY2023 | 3 | 2.00 |
| FY2022 | 1 | (1.00) |
| FY2021 | 2 | 0.00 |
| FY2017 | 2 | (1.00) |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 47.54% | 5.29% | Pass | 1 |
| Positive operating cash flow | (138.51m) | (20.44m) | Fail | 0 |
| Rising return on assets | 47.54% | 5.29% | Pass | 1 |
| Cash flow above net income | (306.54m) | (48.95m) | Fail | 0 |
| Falling long-term leverage | 0.10 | 0.49 | Pass | 1 |
| Rising current ratio | 1.47 | 1.21 | Pass | 1 |
| No new shares issued | 117,143,000 | 114,554,000 | Fail | 0 |
| Rising gross margin | 67.24% | 66.93% | Pass | 1 |
| Rising asset turnover | 0.12 | 0.05 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CHRS Coherus Oncology, Inc. | 6 |
| MDWD MediWound Ltd. compare | 5 |
| WHWK Whitehawk Therapeutics, Inc. compare | 4 |
| ADAG Adagene Inc. Sponsored ADR compare | 4 |
| DTIL Precision BioSciences, Inc. compare | 1 |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0 |
| CMPX Compass Therapeutics, Inc. compare | — |
| ORMP Oramed Pharmaceuticals Inc. compare | — |
| VRXA Veraxa Biotech AG compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover